Failure of SCID-X1 gene therapy in older patients

Molecular Immunology Unit, Institute of Child Health, London, United Kingdom.
Blood (Impact Factor: 9.78). 07/2005; 105(11):4255-7. DOI: 10.1182/blood-2004-12-4837
Source: PubMed

ABSTRACT Gene therapy has been shown to be a highly effective treatment for infants with typical X-linked severe combined immunodeficiency (SCID-X1, gammac-deficiency). For patients in whom previous allogeneic transplantation has failed, and others with attenuated disease who may present later in life, the optimal treatment strategy in the absence of human leukocyte antigen (HLA)-matched donors is unclear. Here we report the failure of gene therapy in 2 such patients, despite effective gene transfer to bone marrow CD34(+) cells, suggesting that there are intrinsic host-dependent restrictions to efficacy. In particular, there is likely to be a limitation to initiation of normal thymopoiesis, and we therefore suggest that intervention for these patients should be considered as early as possible.

Download full-text


Available from: Christophe Hue, Mar 30, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: For over 40 years, primary immunodeficiencies (PIDs) have featured prominently in the development and refinement of human allogeneic hematopoietic stem cell transplantation. More recently, ex vivo somatic gene therapy using autologous cells has provided remarkable evidence of clinical efficacy in patients without HLA-matched stem cell donors and in whom toxicity of allogeneic procedures is likely to be high. Together with improved preclinical models, a wealth of information has accumulated that has allowed development of safer, more sophisticated technologies and protocols that are applicable to a much broader range of diseases. In this review we summarize the status of these gene therapy trials and discuss the emerging application of similar strategies to other PIDs.
    Human gene therapy 06/2012; 23(7):668-75. DOI:10.1089/hum.2012.116 · 3.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cells occupy a special position in cellular hierarchy during differentiation and development of any organism. These undifferentiated cells have the potential to form any other cell type with specialized function and are characterized by their ability to self-renew and to differentiate. Both these cellular properties are prime requisites for the success of current regenerative medicine. Depending upon the potential to differentiate into a particular lineage, stem cells could be grouped into five types (Fig. 2.1). 1. Totipotent: A single cell capable of dividing and forming various differentiated cells including extraembryonic tissues is known as totipotent or omnipotent cell, e.g., a zygote. 2. Pluripotent: The pluripotent stem cells have the ability to differentiate into all cell types of the three germ layers, i.e., ectoderm, mesoderm, and endoderm. Inability to form extraembryonic tissues such as placenta is the only limitation that makes them inferior to totipotent stem cells, e.g., embryonic stem (ES) cells. 3. Multipotent: Stem cells that demonstrate a restricted pattern of differentiation toward few lineages are termed as multipotent cells such as hematopoietic stem cell (HSC), which can develop into various types of blood cells but not into brain or liver cells.
    Engineering in Translational Medicine, Edited by W. Cai, 02/2014: chapter Stem Cells: The Holy Grail of Regenerative Medicine: pages 52; Springer-Verlag London 2014.
  • Source
    Targets in Gene Therapy, 08/2011; , ISBN: 978-953-307-540-2